



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): **Timothy J. Guzi et al.** : Group Art Unit: To Be Assigned  
Serial No.: **10/654,163** : Examiner: To Be Assigned  
Filed: **09/03/2003** : Attorney Docket No. : OC01620K  
For: **NOVEL PYRAZOLOPYRIMIDINES AS**  
**CYCLIN DEPENDENT KINASE INHIBITORS** :  
X

**INFORMATION DISCLOSURE STATEMENT AND**  
**SUBMISSION OF INTERNATIONAL SEARCH REPORT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to Rule 56, it is requested that the documents listed on the accompanying PTO-1449 Form be considered and made of record in the above-identified patent application. Copy(ies) of these references ☒ are attached ☐ were filed in related application U.S. Serial No(s) \_\_\_\_\_ filed \_\_\_\_\_, respectively.

(b) No fee is believed due because:


- ☐ This Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- ☐ This Information Disclosure Statement is being concurrently filed with the above-identified application.
- ☐ This Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- ☒ This Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

(c) ☐ This Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.

March 19, 2004

Page 2 of 2



(d) ☐

This Information Disclosure Statement is being filed on or before the payment of the issue fee; and

☐

Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

☐

No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and

☐

The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.


☒

The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 19-0365, Patent Case No. OC01620K.

Respectfully submitted,  
SCHERING-PLOUGH CORPORATION

Dated: March 19, 2004  
SCHERING-PLOUGH CORPORATION  
Patent Department, K-6-1, 1990  
2000 Galloping Hill Road  
Kenilworth, NJ 07033-0530  
Facsimile No.: (908) 298-5388

By:

  
Name: Palaiyur S. Kalyanaraman  
Reg. No.: 34,634  
**Attorney of Record**  
Telephone No.: (908) 298-5068



Application No.: 10/654,163

Filing Date: 09/03/2003

Applicant: Timothy J. Guzi et al.

Title: "Novel Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors"

### Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on 03/19/2004  
Date

A handwritten signature in black ink, appearing to read "Palaiyur S. Kalyanaraman".

Signature

Palaiyur S. Kalyanaraman, Reg. No. 34,634

Typed or printed name of person signing Certificate

**Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.**

Documents enclosed:

Certificate of Mailing - 1pg.

Information Disclosure Statement - 2pgs.

PTO-1449 Form - 1pg. in duplicate


References (8)

Copy of International Search Report - 4pgs.

Post Card

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

APPLICATION NO.:

OC01620K

10/654,163

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

APPLICANT:

Timothy J. Guzi *et al.*

(Use several sheets if necessary)

FILING DATE:

09/03/2003

GROUP:

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	AL	DE 102 23 917 A1	12/11/2003	Germany				
	AM	EP 1 199 306 A1	04/24/2002	Europe				
	AN	EP 0 714 898 A1	06/05/1996	Europe				
	AO	WO 02/50079 A1	06/27/2002	WIPO				
	AP	WP 03/091256 A1	11/06/2003	WIPO				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AQ	Adrian M. Senderowicz <i>et al.</i> , "Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators", <i>J. Natl. Cancer Inst.</i> , <b>92</b> (5):376-387 (March 1, 2000).						
	AR	Teruki Honma <i>et al.</i> , "Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors: New <i>de Novo</i> Design Strategy and Library Design", <i>J. Med. Chem.</i> , <b>44</b> : 4615-4627 (2001).						
	AS	Translation of WO 03/91256, <i>A Rising Sun Communications Ltd. Translation Product</i> , (1-62).						
	AT							
	AU							
	AV							

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



# DUPLICATE

Sheet 1 of 1

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: <b>OC01620K</b>		APPLICATION NO.: <b>10/654,163</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT: <b>Timothy J. Guzi et al.</b>			
				FILING DATE: <b>09/03/2003</b>		GROUP:	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL	DE 102 23 917 A1	12/11/2003	Germany			
	AM	EP 1 199 306 A1	04/24/2002	Europe			
	AN	EP 0 714 898 A1	06/05/1996	Europe			
	AO	WO 02/50079 A1	06/27/2002	WIPO			
	AP	WP 03/091256 A1	11/06/2003	WIPO			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	AQ	Adrian M. Senderowicz et al., "Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators", <i>J. Natl. Cancer Inst.</i> , <b>92</b> (5):376-387 (March 1, 2000).					
	AR	Teruki Honma et al., "Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors: New de Novo Design Strategy and Library Design", <i>J. Med. Chem.</i> , <b>44</b> : 4615-4627 (2001).					
	AS	Translation of WO 03/91256, <i>A Rising Sun Communications Ltd. Translation Product</i> , (1-62).					
	AT						
	AU						
	AV						
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							